NVCR
Income statement / Annual
Last year (2024), NovoCure Limited's total revenue was $605.22 M,
an increase of 18.82% from the previous year.
In 2024, NovoCure Limited's net income was -$168.63 M.
See NovoCure Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$605.22 M |
$509.34 M |
$537.84 M |
$535.03 M |
$494.37 M |
$351.32 M |
$248.07 M |
$177.03 M |
$82.89 M |
$33.09 M |
| Cost of Revenue |
$137.18 M
|
$128.28 M
|
$114.87 M
|
$114.88 M
|
$106.50 M
|
$88.61 M
|
$80.05 M
|
$55.61 M
|
$46.28 M
|
$20.61 M
|
| Gross Profit |
$468.04 M
|
$381.06 M
|
$422.97 M
|
$420.15 M
|
$387.87 M
|
$262.71 M
|
$168.02 M
|
$121.42 M
|
$36.61 M
|
$12.48 M
|
| Gross Profit Ratio |
0.77
|
0.75
|
0.79
|
0.79
|
0.78
|
0.75
|
0.68
|
0.69
|
0.44
|
0.38
|
| Research and Development Expenses |
$209.65 M
|
$223.06 M
|
$206.09 M
|
$201.30 M
|
$132.01 M
|
$79.00 M
|
$50.57 M
|
$38.10 M
|
$41.47 M
|
$43.75 M
|
| General & Administrative Expenses |
$189.83 M
|
$164.06 M
|
$132.75 M
|
$126.13 M
|
$107.44 M
|
$87.95 M
|
$73.46 M
|
$59.11 M
|
$51.01 M
|
$33.86 M
|
| Selling & Marketing Expenses |
$239.06 M
|
$226.81 M
|
$173.66 M
|
$137.06 M
|
$118.02 M
|
$96.68 M
|
$77.66 M
|
$63.53 M
|
$59.45 M
|
$38.86 M
|
| Selling, General & Administrative Expenses |
$428.89 M
|
$390.87 M
|
$306.41 M
|
$263.18 M
|
$225.45 M
|
$184.62 M
|
$151.12 M
|
$122.64 M
|
$110.46 M
|
$72.73 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$638.54 M
|
$614.67 M
|
$512.50 M
|
$464.49 M
|
$357.46 M
|
$263.63 M
|
$201.69 M
|
$160.75 M
|
$151.92 M
|
$116.47 M
|
| Cost And Expenses |
$775.72 M
|
$742.21 M
|
$627.36 M
|
$579.36 M
|
$463.97 M
|
$352.23 M
|
$281.74 M
|
$216.35 M
|
$198.21 M
|
$137.08 M
|
| Interest Income |
$22.72 M
|
$46.04 M
|
$10.96 M
|
$791,000.00
|
$1.79 M
|
$4.40 M
|
$2.65 M
|
$1.12 M
|
$659,000.00
|
$84,000.00
|
| Interest Expense |
-$17.33 M
|
$3.32 M
|
$3.33 M
|
$3.44 M
|
$13.15 M
|
$13.72 M
|
$13.49 M
|
$10.26 M
|
$5.94 M
|
$2.37 M
|
| Depreciation & Amortization |
$11.24 M
|
$10.97 M
|
$10.62 M
|
$10.25 M
|
$9.15 M
|
$8.39 M
|
$9.01 M
|
$7.68 M
|
$5.65 M
|
$3.15 M
|
| EBITDA |
-$109.58 M |
-$175.87 M |
-$63.11 M |
-$38.38 M |
$45.30 M |
$14.21 M |
-$23.45 M |
-$29.13 M |
-$108.89 M |
-$101.12 M |
| EBITDA Ratio |
-0.18
|
-0.35
|
-0.17
|
-0.08
|
0.06
|
-0
|
-0.14
|
-0.22
|
-1.39
|
-3.14
|
| Operating Income Ratio |
-0.28
|
-0.46
|
-0.17
|
-0.08
|
0.04
|
-0
|
-0.14
|
-0.22
|
-1.39
|
-3.14
|
| Total Other Income/Expenses Net |
$39.33 M
|
$41.13 M
|
$7.68 M
|
-$7.74 M
|
-$12.30 M
|
-$7.91 M
|
-$12.27 M
|
-$9.17 M
|
-$6.15 M
|
-$3.15 M
|
| Income Before Tax |
-$131.16 M
|
-$191.74 M
|
-$81.85 M
|
-$52.08 M
|
$18.10 M
|
-$8.82 M
|
-$45.94 M
|
-$48.50 M
|
-$121.46 M
|
-$107.15 M
|
| Income Before Tax Ratio |
-0.22
|
-0.38
|
-0.15
|
-0.1
|
0.04
|
-0.03
|
-0.19
|
-0.27
|
-1.47
|
-3.24
|
| Income Tax Expense |
$37.47 M
|
$15.30 M
|
$10.69 M
|
$6.28 M
|
-$1.71 M
|
-$1.59 M
|
$17.62 M
|
$13.17 M
|
$10.38 M
|
$4.43 M
|
| Net Income |
-$168.63 M
|
-$207.04 M
|
-$92.53 M
|
-$58.35 M
|
$19.81 M
|
-$7.23 M
|
-$63.56 M
|
-$61.66 M
|
-$131.85 M
|
-$111.58 M
|
| Net Income Ratio |
-0.28
|
-0.41
|
-0.17
|
-0.11
|
0.04
|
-0.02
|
-0.26
|
-0.35
|
-1.59
|
-3.37
|
| EPS |
-1.56 |
-1.95 |
-0.88 |
-0.56 |
0.2 |
-0.0744 |
-0.69 |
-0.7 |
-1.54 |
-3.67 |
| EPS Diluted |
-1.56 |
-1.95 |
-0.88 |
-0.56 |
0.18 |
-0.0744 |
-0.69 |
-0.7 |
-1.54 |
-3.67 |
| Weighted Average Shares Out |
$107.83 M
|
$106.39 M
|
$104.66 M
|
$103.43 M
|
$100.93 M
|
$97.24 M
|
$91.83 M
|
$88.55 M
|
$85.56 M
|
$30.40 M
|
| Weighted Average Shares Out Diluted |
$107.83 M
|
$106.39 M
|
$104.66 M
|
$103.43 M
|
$108.88 M
|
$97.24 M
|
$91.83 M
|
$88.55 M
|
$85.56 M
|
$30.40 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
